Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
Will add UNLOXCYT (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm franchise
Imfinzi reduced the risk of distant metastases and death from bladder cancer vs. neoadjuvant chemotherapy alone
Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone
Prithwish has close to 28 years of experience in a Commercial role
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
Subscribe To Our Newsletter & Stay Updated
